Abstracts tagged "juvenile idiopathic arthritis (JIA)"

Abstract Number: 2404 • 2018 ACR/ARHP Annual Meeting
Quality of Life Assessment in Juvenile Idiopathic Arthritis: A Single Center Assessment
W. Blaine Lapin¹, Taylor Phillips², Danielle Guttman-Lapin³, Amanda Brown⁴, Eyal Muscal⁵ and Filiz O. Seeborg¹, ¹Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, ²Rice University, Houston, TX, ³Aldine Independent School District, Aldine, TX, ⁴Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, Baylor College of Medicine, houston, TX, ⁵Department of Pediatrics, Division of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Houston, TX
Background/Purpose: Patients with Juvenile Idiopathic Arthritis (JIA) face physical, social, and emotional issues that affect their quality of life. Health-related quality of life (HRQoL) is…
Abstract Number: 2405 • 2018 ACR/ARHP Annual Meeting
Health-Related Quality of Life, Functioning, and Mental Health of Children with Chronic Non-Infectious Uveitis
Joseph McDonald¹, Curtis Travers², Courtney McCracken², Steven Yeh³, Kelly A. Rouster-Stevens⁴, Patricia Vega-Fernandez⁴, Elaine Ramsay⁴, Sampath Prahalad⁴, Carolyn Drews-Botsch⁵ and Sheila Angeles-Han⁶, ¹Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Pediatrics, Emory University School of Medicine, Atlanta, GA, ³Ophthalmology, Emory University School of Medicine, Atlanta, GA, ⁴Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, ⁵Epidemiology, Emory University School of Public Health, Atlanta, GA, ⁶Rheumatology, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, OH
Background/Purpose: Pediatric chronic non-infectious uveitis can lead to ocular complications and vision loss. The ophthalmic clinical exam is primarily used to assess uveitis outcomes but…
Abstract Number: 2407 • 2018 ACR/ARHP Annual Meeting
New Onset of Uveitis in Non-Methotrexate Group, Methotrexate Group and Etanercept Group in Juvenile Idiopathic Arthritis
Mikhail Kostik, Ekaterina Gaidar, Maria Likhacheva, Eugenia Isupova, Irina Chikova, Margarita Dubko, Vera Masalova, Tatiana Likhacheva, Ludmila Snegireva, Tatiana Kornishina, Olga Kalashnikova and Vyacheslav Chasnyk, Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russian Federation
Background/Purpose: Uveitis is the most common extra-articular manifestation of juvenile idiopathic arthritis (JIA), often entirely asymptomatic but could be sight-threatening. The most often prescribed biologics…
Abstract Number: 2409 • 2018 ACR/ARHP Annual Meeting
Do Children with Juvenile Idiopathic Arthritis Play an Active Role in Their Treatment Adherence? First Results of the Rumaji Study
Guillaume Montagu¹, Ellie Mevel¹, William FAHY², Linda Rossi-Semerano³, Elisabeth Solau-Gervais⁴, Sonia Tropé⁵ and Jean-David Cohen⁶, ¹Research, Unknowns, strategy and innovation consulting, PARIS, France, ²KOURIR, Paris, France, ³Paediatric Rheumatology, Hôpital Kremlin Bicêtre, PARIS, France, ⁴Service de Rhumatologie, CHRU de Poitiers, Poitiers, France, ⁵149 avenue du Maine, ANDAR, Paris, France, ⁶IMMUNO-RHEUMATOLOGY, CHU LAPEYRONIE, MONTPELLIER, France
Background/Purpose: Adherence to DMARDs such as methotrexate and biologics is critical for patients with Juvenile Idiopathic Arthritis (JIA). Notwithstanding, few studies exists on that topic…
Abstract Number: 979 • 2018 ACR/ARHP Annual Meeting
Stopping Medicines for Inactive Juvenile Idiopathic Arthritis: What Do Patients and Families Consider?
Daniel B. Horton^1,2, Jomaira Salas³, Aleksandra Wec⁴, Timothy Beukelman⁵, Alexis Boneparth⁶, Jaime Guzman⁷, Ky Haverkamp⁸, Melanie Kohlheim⁹, Melissa L. Mannion⁵, Nandini Moorthy¹, Elizabeth Stringer¹⁰, Lori Tucker⁷, Sarah Ringold¹¹ and Marsha Rosenthal², ¹Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²Rutgers Institute for Health, Health Care Policy and Aging Research, New Brunswick, NJ, ³Department of Sociology, Rutgers, the State University of New Jersey, New Brunswick, NJ, ⁴Mathematica Policy Research, Princeton, NJ, ⁵Pediatrics, University of Alabama at Birmingham, Birmingham, AL, ⁶Pediatrics, Columbia University Medical Center, New York, NY, ⁷Rheumatology, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ⁸Family Medicine, University of Washington School of Medicine, Seattle, WA, ⁹Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, OH, ¹⁰IWK Health Centre, Dalhousie University, Halifax, NS, Canada, ¹¹Pediatrics, Seattle Children's Hospital, Seattle, WA
Background/Purpose: Prior research has focused on factors important to clinicians in decisions about withdrawing JIA therapy. Based on recent interviews with patients and caregivers about…
Abstract Number: 2420 • 2018 ACR/ARHP Annual Meeting
Pregnancy Outcome and Perinatal Complications of Neonate Born to Mothers with Juvenile Idiopathic Arthritis in Asia
Chao-Yi Wu¹, Shang-Chun Changchien², Huang-Yu Yang³, Kuo-Wei Yeh⁴ and Jing-Long Huang^1,2, ¹Division of Allergy, Asthma and Rheumatology. Department of Pediatrics, Chang-Gung Memorial Hospital, Taoyuan city, Taiwan, ²Medicine, Chang-Gung University, Taoyuan city, Taiwan, ³Department of Nephrology,, Chang-Gung Memorial Hospital, Taoyuan city, Taiwan, ⁴Division of Allergy, Asthma and Rheumatology. Department of Pediatrics, Chang-Gung Memorial Hospital, Taoyuan, Taiwan
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the leading pediatric rheumatic disease affecting 30 out of a million women. Although spontaneous remission may occur in most…
Abstract Number: 1849 • 2018 ACR/ARHP Annual Meeting
Remission Status after 18 Years of Follow-up in the Population-Based Nordic Juvenile Idiopathic Arthritis (JIA) Cohort
Mia Glerup¹, Veronika Rypdal^2,3, Ellen Dalen Arnstad^4,5, Maria Ekelund^6,7, Suvi Peltoniemi⁸, Kristiina Aalto⁸, Marite Rygg^9,10, Peter Toftedal¹¹, Susan Nielsen¹¹, Anders Fasth¹², Lillemor Berntson¹³, Ellen Nordal^14,15 and Troels Herlin¹⁶, ¹Department of Pediatrics, Dept. of Pediatrics, Aarhus University Hospital, Denmark, Aarhus, Denmark, ²Dept. of Clin. Med, UIT The Arctic University of Norway, Tromsø, Norway, ³Dept. of Pediatrics, University Hospital of North Norway, Tromsø, Norway, ⁴Dept. Clin. and Mol. Med., NTNU, Norway, Trondheim, Norway, ⁵Dept. of Pediatrics, Levanger Hospital, Nord-Trøndelag, Norway, Trondheim, Norway, ⁶Department of Pediatrics, Dept. of Pediatrics, Ryhov County Hospital, Jonkoping, Sweden, Jonkoping, Sweden, ⁷Uppsala University, Uppsala, Sweden, Jonkobing, Sweden, ⁸Hospital for Children and Adolescents, University of Helsinki, Finland, Helsinki, Finland, ⁹Dep. Clin. and Mol. Med., Dept. Clin. and Mol. Med., NTNU, Norway, Trondheim, Norway, ¹⁰Department of Pediatrics, Dept. of Pediatrics, St. Olavs Hospital, Norway, Trondheim, Norway, ¹¹Department of Pediatrics, Dept. of Pediatrics, Copenhagen University Hospital, Denmark, Copenhagen, Denmark, ¹²Sahlgrenska Academy, University of Gothenburg, Sweden, Gothenburg, Sweden, ¹³Uppsala University, Uppsala, Sweden, Uppsala, Sweden, ¹⁴Departments of Pediatrics, Dept. of Pediatrics, University Hospital of North Norway, Tromsø, Norway, ¹⁵Department of Clinical Medicine, Dept. of Clin. Med, UIT The Arctic University of Norway, Tromsø, Norway, ¹⁶Dept. of Pediatrics, Aarhus University Hospital, Aarhus N, Denmark
Background/Purpose: Innovative changes towards targeted treatment have improved the outcome dramatically for juvenile idiopathic arthritis (JIA) but the question remains how well these patients perform…
Abstract Number: 2916 • 2018 ACR/ARHP Annual Meeting
New JADAS10- and cJADAS10-Based Cutoffs for Juvenile Idiopathic Arthritis Disease Activity States: Validation in a Multinational Dataset of 4830 Patients
Alessandro Consolaro^1,2, Chiara Trincianti¹, Pieter van Dijkhuizen³, Giedre Januskeviciute⁴, Gabriella Giancane⁵, Alessandra Alongi¹, Joost Swart³, Nicola Ruperto^6,7 and Angelo Ravelli^2,8, ¹University of Genova, Genova, Italy, ²Clinica Pediatrica - Reumatologia, Istituto Giannina Gaslini, Genova, Italy, ³UMC Utrecht, Wilhelmina Children’s Hospital, Utrecht, Netherlands, ⁴Istituto Giannina Gaslini, Genova, Italy, ⁵Clinica Pediatrica - Reumatologia, Istituto Giannina Gaslini, Genoa, Italy, ⁶Universita di Genova Pediatria II, Genova, Italy, ⁷Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ⁸University of Genova, Genoa, Italy
Background/Purpose: The Juvenile Arthritis Disease Activity Score (JADAS) and its clinical version excluding the acute phase reactant (cJADAS) were developed for measuring disease activity in…
Abstract Number: 2017 • 2018 ACR/ARHP Annual Meeting
Oral Microbiota in New-Onset Juvenile Idiopathic Arthritis
Albert Chow^1,2,3, Sriharsha Grevich^1,2,3, Peggy Lee⁴, Jeffrey McLean⁴, Sarah Ringold^1,3,5, Roger Bumgarner⁶ and Anne Stevens^1,2,3, ¹Pediatrics, University of Washington, Seattle, WA, ²Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA, ³Pediatric Rheumatology, Seattle Children's Hospital, Seattle, WA, ⁴Dentistry, University of Washington, Seattle, WA, ⁵Center for Clinical and Translational Research, Seattle Children's Research Institute, Seattle, WA, ⁶Microbiology, University of Washington, Seattle, WA
Background/Purpose: Oral microbial dysbiosis of specific organisms such as Porphyromonas, Aggregatibacter, Tannerella, and Treponema in dental plaque has been implicated in the pathogenesis of adult…
Abstract Number: 2918 • 2018 ACR/ARHP Annual Meeting
Physical Activity in Canadian Children with Juvenile Idiopathic Arthritis: The LEAP Study (Linking Exercise, Activity, and Pathophysiology in Canadian Children with Arthritis)
Lori Tucker¹, Jaime Guzman¹, Kristin Houghton², Dax G. Rumsey³, Elizabeth Stringer⁴, Shirley M.L. Tse⁵, Rosie Scuccimarri⁶, Claire LeBlanc⁷, Roberta Berard⁸, Bianca Lang⁹, Karen N Watanabe Duffy¹⁰ and Ciarán M. Duffy¹¹, ¹BC Children's Hospital, Vancouver, BC, Canada, ²Rheumatology/Pediatrics, British Columbia Children's Hospital, Vancouver, BC, Canada, ³Stollery Children's Hospital, Edmonton, AB, Canada, ⁴Department of Rheumatology, IWK Health Centre, Halifax, NS, Canada, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶Department of Pediatrics, McGill University Health Centre, Montreal, QC, Canada, ⁷Pediatrics, Montreal Children's Hospital, Montreal, QC, Canada, ⁸Pediatrics, Children's Hospital, London Health Sciences Centre, London, ON, Canada, ⁹Pediatrics, IWK Health Centre, Halifax, NS, Canada, ¹⁰Rheumatology, Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ¹¹Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada
Background/Purpose: Physical activity (PA) is an important component of health, and is essential for optimal growth and development. Children with juvenile idiopathic arthritis (JIA) are…
Abstract Number: 2018 • 2018 ACR/ARHP Annual Meeting
Microenvironment Driven Re-Shaping of Pathogenic T Effector and Regulatory Subset in Active Juvenile Idiopathic Arthritic Patients
Jing Yao Leong¹, Pavanish Kumar¹, Phyllis Chen², Joo Guan Yeo^2,3, Camillus Chua², Sharifah Nur Hazirah², Suzan Saidin¹, Thaschawee Arkachaisri^2,3, Alessandro Consolaro⁴, Marco Gattorno⁵, Alberto Martini⁶ and Salvatore Albani², ¹Translational Immunology Institute, Singhealth/Duke-NUS Academic Medical Centre, Singapore, Singapore, ²Translational Immunology Institute, Singhealth/Duke-NUS Academic Medical Centre, Singapore Health Services Pte Ltd, Singapore, Singapore, ³KK Women's and Children's Hospital, Singapore, Singapore, ⁴Second Paediatric Division, University of Genoa and G Gaslini Institute, Genova, Italy, Genova, Italy, ⁵Second Paediatric Division, University of Genoa and G Gaslini Institute, Genova, Italy, Genoa, Italy, ⁶Pediatric Rheumatology International Trial Organization (PRINTO) Coordinating Centre, Genoa, Italy
Background/Purpose: We have previously identified two CD4 pathogenic circulatory subsets in both T effector (CPLs) and T regulatory (iaTreg) compartments that are both HLA-DR+, antigen…
Abstract Number: 2963 • 2018 ACR/ARHP Annual Meeting
Improving Clinically Inactive Disease in Patients with Juvenile Idiopathic Arthritis- a Quaternary Center Experience
Cagri Yildirim-Toruner¹, Ohoud AlAhmed², Fatima Barbar-Smiley³, Karla Jones³, Melanie Kohlheim⁴, Stephanie Lemle⁵, Darby MacDonald², Evan Mulvihill⁶, Edward Oberle², Aliese Sarkissian², Vidya Sivaraman⁷, Bethanne Thomas², Kelly Wise⁸ and Stacy P. Ardoin¹, ¹Division of Rheumatology, Nationwide Children’s Hospital, Columbus, OH, ²Pediatric Rheumatology, Nationwide Children's Hospital, Columbus, OH, ³Rheumatology, Nationwide Children's Hospital, Columbus, OH, ⁴Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, OH, ⁵Nationwide Children's Hospital, Columbus, OH, ⁶Pediatrics and Rheumatology, Nationwide Children's Hospital, Columbus, OH, ⁷Division of Rheumatology, Nationwide Children's Hospital, Columbus, OH, ⁸Specialty Pharmacy/Rheumatology, Nationwide Children's Hospital, Columbus, OH
Background/Purpose: Juvenile idiopathic arthritis (JIA), the most common pediatric rheumatologic diagnosis, influences many aspects of a child’s life. Although there is no known cure, disease…
Abstract Number: 2027 • 2018 ACR/ARHP Annual Meeting
Whole Exome Trio Sequencing Implicates DOCK2 in Juvenile Idiopathic Arthritis
Laura A McIntosh^1,2, Yoshinori Fukui³, Thomas A. Griffin⁴, Kenneth Kaufman^1,2,5, Jarek Meller^6,7, Sherry Thornton⁸, Halima Moncrieffe^1,2 and Susan D Thompson^1,2, ¹Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Department of Pediatrics, University of Cincinnati, Cincinnati, OH, ³Division of Immunogenetics, Department of Immunobiology and Neuroscience, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan, ⁴Levine Children’s Hospital at Carolinas Medical Center, Charlotte, NC, ⁵US Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁶Division of Biomedical Informatics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁷Department of Environmental Health, University of Cincinnati, Cincinnati, OH, ⁸Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease of childhood and has a strong genetic component to disease risk. Genome-wide association studies…
Abstract Number: 2378 • 2018 ACR/ARHP Annual Meeting
Subcutaneous Abatacept in Patients Aged 2–17 Years with Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Results over 24 Months By Juvenile Idiopathic Arthritis Disease Category
Nicola Ruperto¹, Hermine I. Brunner², Gabriel Vega-Cornejo³, Alberto Berman⁴, Rubén J. Cuttica⁵, Francisco Ávila-Zapata⁶, Michael Henrickson⁷, Daniel J Kingsbury⁸, John F. Bohnsack⁹, Thomas Lutz¹⁰, Nadina E Rubio-Pérez¹¹, Valeria Gerloni¹², Xiaohui Li¹³, Marleen Nys¹⁴, Robert Wong¹³, Alberto Martini¹⁵ and Daniel J Lovell¹⁶, ¹Istituto Giannina Gaslini - Clinica Pediatrica e Reumatologia, Genoa, Italy, ²Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Clinica de Reumatología y Enfermedades Autoinmunes (CREA), Hospital México Americano, Guadalajara Jalisco, Mexico, ⁴Centro Médico Privado de Reumatología, Tucumán, Argentina, ⁵Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina, ⁶Star Medica Hospital, Merida, Yucatán, Mexico, ⁷Cincinnati Children’s Medical Center, Cincinnati, OH, ⁸Randall Children’s Hospital at Legacy Emanuel, Portland, OR, ⁹University of Utah School of Medicine, Salt Lake City, UT, ¹⁰Pediatric Rheumatology, University Hospital, Center for Pediatric and Adolescent Medicine / Clinic 1, Heidelberg, Germany, ¹¹Universidad Autónoma de Nuevo León, Monterrey Nuevo León, Mexico, ¹²Istituto Gaetano Pini, Milan, Italy, ¹³Bristol-Myers Squibb, Princeton, NJ, ¹⁴Bristol-Myers Squibb, Braine L’Alleud, Belgium, ¹⁵Istituto G. Gaslini Pediatria II Reumatologia and University of Genova, Genova, Italy, ¹⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: The effect of biologic DMARDs on different juvenile idiopathic arthritis (JIA) categories is poorly understood. In patients (pts) with JIA aged 2–17 years (y),…
Abstract Number: 2389 • 2018 ACR/ARHP Annual Meeting
Evaluating Disease Activity Outcomes for Juvenile Idiopathic Arthritis across the Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN)
Emily A. Smitherman¹, Bin Huang², Ronald M. Laxer³, C. April Bingham⁴, Cagri Yildirim-Toruner⁵, Beth Gottlieb⁶, Jennifer Weiss⁷, Tzielan Lee⁸, Sheetal S. Vora⁹, Jon (Sandy) Burnham¹⁰, Julia Harris¹¹, Judyann C. Olson¹², Mileka Gilbert¹³, Michelle Batthish¹⁴, Michael Shishov¹⁵, Dustin Fleck¹⁶ and Esi Morgan¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Div of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Penn State Health Children's Hospital, Hershey, PA, ⁵Division of Rheumatology, Nationwide Children’s Hospital, Columbus, OH, ⁶Pediatric Rheumatology PTD, Cohen Children's Medical Center of New York, Lake Success, NY, ⁷Hackensack University Medical Center, Hackensack, NJ, ⁸Pediatric Rheumatology, Stanford University, Palo Alto, CA, ⁹Pediatric Rheumatology, Levine Children's Hospital, Charlotte, NC, ¹⁰Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ¹¹Children's Mercy - Kansas City, Kansas City, MO, ¹²Ped/MACC Fund Research Ctr, Medical College of Wisconsin, Milwaukee, WI, ¹³Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, ¹⁴Division of Pediatric Rheumatology, McMaster Children's Hospital, Hamilton, ON, Canada, ¹⁵Phoenix Children's Hospital, Phoenix, AZ, ¹⁶Pediatric Rheumatology, University of Michigan, Brighton, MI
Background/Purpose: It is widely accepted that the treatment goal for juvenile idiopathic arthritis (JIA) is remission. PR-COIN, a quality improvement collaborative comprised of pediatric rheumatology…

« Previous Page
1
…
5
6
7
8
9
…
19
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].